

Enhanced Drug List Updates

January 2023

TRADE NAME (generic name)	Brand/Generic	
	Product	Description of Change
NEXAVAR (sorafenib tosylate tab 200 mg (base equivalent))	Brand	Removal, Non-Preferred Status, generics available
SKYRIZI (risankizumab-rzaa subcutaneous soln cartridge 360 mg/2.4ml)	Brand	Addition, Preferred Status
TRIUMEQ PD (abacavir-dolutegravir-lamivudine tab for oral sus 60-5-30 mg)	Brand	Addition, Preferred Status
VEMLIDY (tenofovir alafenamide fumarate tab 25 mg)	Brand	Addition, Preferred Status
VIMPAT (lacosamide oral solution 10 mg/ml)	Brand	Removal, Non-Preferred Status, generics available

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.